Catalytic activity of APOBEC3F is required for efficient restriction of Vif-deficient human immunodeficiency virus

Virology

Volumn 450-451, Issue , 2014, Pages 49-54

  Albin, John S ^a   Brown, William L ^a   Harris, Reuben S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

APOBEC3F; APOBEC3G; Deaminase; HIV restriction; Vif

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CYTOSINE DEAMINASE; VIF PROTEIN;

ARTICLE; ENZYME ACTIVITY; ENZYME MECHANISM; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; MOLECULAR MECHANICS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; STABLE EXPRESSION; T LYMPHOCYTE; VIRUS INFECTION; VIRUS REPLICATION; WILD TYPE;

APOBEC3F; APOBEC3G; DEAMINASE; HIV RESTRICTION; VIF;

BIOCATALYSIS; CELL LINE; CYTIDINE DEAMINASE; CYTOSINE DEAMINASE; GENE PRODUCTS, VIF; HIV INFECTIONS; HIV-1; HUMANS; PROTEIN BINDING; T-LYMPHOCYTES; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84890827096     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2013.11.041     Document Type: Article

References (48)

1. Albin J.S., Harris R.S. Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Rev. Mol. Med. 2010, 12:1-26.
2. Albin J.S., Haché G., Hultquist J.F., Brown W.L., Harris R.S. Long-term restrictionby APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function. J. Virol. 2010, 84:10209-10219.
3. Albin J.S., LaRue R.S., Weaver J.A., Brown W.L., Shindo K., Harjes E., Matsuo H., Harris R.S. A single amino acid in human APOBEC3F alters susceptibility to HIV-1 Vif. The Journal of Biological Chemistry 2010, 285:40785-40792.
4. Albin J.S., Anderson J.S., Johnson J.R., Harjes E., Matsuo H., Krogan N.J., Harris R.S. Dispersed sites of HIV Vif-dependent polyubiquitination in the DNA deaminase APOBEC3F. J. Mol. Biol. 2013, 425:1172-1182.
5. Albin J.S., Harris R.S. APOBECs and their role in proviral DNA synthesis. Human Immunodeficiency Virus Reverse Transcriptase: A Bench-to-Bedside Success 2013, 253-280. Springer, New York, NY. S.F. Le Grice, M. Goette (Eds.).
6. Bishop K.N., Holmes R.K., Malim M.H. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J. Virol. 2006, 80:8450-8458.
7. Bishop K.N., Verma M., Kim E.Y., Wolinsky S.M., Malim M.H. APOBEC3G inhibitselongation of HIV-1 reverse transcripts. PLoS Pathog. 2008, 4:e1000231.
8. Browne E.P., Allers C., Landau N.R. Restriction of HIV-1 by APOBEC3G is cytidine deaminase-dependent. Virology 2009, 387:313-321.
9. Chaipan C., Smith J.L., Hu W.S., Pathak V.K. APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages. J. Virol. 2013, 87:444-453.
10. Gillick K., Pollpeter D., Phalora P., Kim E.Y., Wolinsky S.M., Malim M.H. Suppression of HIV-1 infection by APOBEC3 proteins in primary human CD4(+) T cells is associated with inhibition of processive reverse transcription as well as excessive cytidine deamination. J. Virol. 2013, 87:1508-1517.
11. Guo F., Cen S., Niu M., Saadatmand J., Kleiman L. Inhibition of formula-primedreverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication. J. Virol. 2006, 80:11710-11722.
12. Haché G., Abbink T.E., Berkhout B., Harris R.S. Optimal translation initiation enables Vif-deficient human immunodeficiency virus type 1 to escape restriction by APOBEC3G. J. Virol. 2009, 83:5956-5960.
13. Haché G., Shindo K., Albin J.S., Harris R.S. Evolution of HIV-1 isolates that use anovel Vif-independent mechanism to resist restriction by human APOBEC3G. Curr. Biol. 2008, 18:819-824.
14. Han Y., Wang X., Dang Y., Zheng Y.H. APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication. PLoS Pathog. 2008, 4:e1000095.
15. Harris R.S., Bishop K.N., Sheehy A.M., Craig H.M., Petersen-Mahrt S.K., Watt I.N., Neuberger M.S., Malim M.H. DNA deamination mediates innate immunity to retroviral infection. Cell 2003, 113:803-809.
16. He Z., Zhang W., Chen G., Xu R., Yu X.F. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction. J. Mol. Biol. 2008, 381:1000-1011.
17. Holmes R.K., Koning F.A., Bishop K.N., Malim M.H. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J. Biol. Chem. 2007, 282:2587-2595.
18. Hultquist J.F., Lengyel J.A., Refsland E.W., Larue R.S., Lackey L., Brown W.L., Harris R.S. Human and Rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J. Virol. 2011, 85(21):11220-11234.
19. Iwatani Y., Chan D.S., Wang F., Maynard K.S., Sugiura W., Gronenborn A.M., Rouzina I., Williams M.C., Musier-Forsyth K., Levin J.G. Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res. 2007, 35:7096-7108.
20. Li X.Y., Guo F., Zhang L., Kleiman L., Cen S. APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription. J. Biol. Chem. 2007, 282:32065-32074.
21. Luo K., Wang T., Liu B., Tian C., Xiao Z., Kappes J., Yu X.F. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. J. Virol. 2007, 81:7238-7248.
22. Malim M.H., Bieniasz P.D. HIV restriction factors and mechanisms of evasion. Cold Spring Harb. Perspect. Med. a006940 2012, 2.
23. Mangeat B., Turelli P., Caron G., Friedli M., Perrin L., Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 2003, 424:99-103.
24. Mbisa J.L., Barr R., Thomas J.A., Vandegraaff N., Dorweiler I.J., Svarovskaia E.S., Brown W.L., Mansky L.M., Gorelick R.J., Harris R.S., Engelman A., Pathak V.K. Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J. Virol. 2007, 81:7099-7110.
25. Mbisa J.L., Bu W., Pathak V.K. APOBEC3F and APOBEC3G inhibit HIV-1 DNAintegration by different mechanisms. J. Virol. 2010, 84:5250-5259.
26. Miyagi E., Brown C.R., Opi S., Khan M., Goila-Gaur R., Kao S., Walker R.C., Hirsch V., Strebel K. Stably expressed APOBEC3F has negligible antiviral activity. J. Virol. 2010, 84:11067-11075.
27. Miyagi E., Opi S., Takeuchi H., Khan M., Goila-Gaur R., Kao S., Strebel K. Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1. J. Virol. 2007, 81:13346-13353.
28. Mulder L.C., Ooms M., Majdak S., Smedresman J., Linscheid C., Harari A., Kunz A., Simon V. Moderate influence of human APOBEC3F on HIV-1 replication in primary lymphocytes. J. Virol. 2010, 84:9613-9617.
29. Nagao T., Yamashita T., Miyake A., Uchiyama T., Nomaguchi M., Adachi A. Different interaction between HIV-1 Vif and its cellular target proteins APOBEC3G/APOBEC3F. J. Med. Invest. 2010, 57:89-94.
30. Newman E.N., Holmes R.K., Craig H.M., Klein K.C., Lingappa J.R., Malim M.H., Sheehy A.M. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr. Biol. 2005, 15:166-170.
31. Pery E., Rajendran K.S., Brazier A.J., Gabuzda D. Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif. J. Virol. 2009, 83:2374-2381.
32. Refsland E.W., Harris R.S. The APOBEC3 family of retroelement restriction factors. Curr. Top. Microbiol. Immunol. 2013, 371:1-27.
33. Refsland E.W., Hultquist J.F., Harris R.S. Endogenous origins of HIV-1G-to-A hypermutation. PLoS Pathog. 2012, 8:e1002800.
34. Refsland E.W., Stenglein M.D., Shindo K., Albin J.S., Brown W.L., Harris R.S. Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res. 2010, 38:4274-4284.
35. Russell R.A., Moore M.D., Hu W.S., Pathak V.K. APOBEC3G induces a hypermutation gradient: purifying selection at multiple steps during HIV-1 replication results in levels of G-to-A mutations that are high in DNA, intermediate in cellular viral RNA, and low in virion RNA. Retrovirology 2009, 6:16.
36. Russell R.A., Pathak V.K. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J. Virol. 2007, 81:8201-8210.
37. Schröfelbauer B., Senger T., Manning G., Landau N.R. Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G. J. Virol. 2006, 80:5984-5991.
38. Schumacher A.J., Haché G., MacDuff D.A., Brown W.L., Harris R.S. The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction. J. Virol. 2008, 82:2652-2660.
39. Shindo K., Takaori-Kondo A., Kobayashi M., Abudu A., Fukunaga K., Uchiyama T. The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity. J. Biol. Chem. 2003, 278:44412-44416.
40. Simon V., Zennou V., Murray D., Huang Y., Ho D.D., Bieniasz P.D. Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog. 2005, 1:e6.
41. Smith J.L., Bu W., Burdick R.C., Pathak V.K. Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development. Trends Pharmacol. Sci. 2009, 30:638-646.
42. Tian C., Yu X., Zhang W., Wang T., Xu R., Yu X.F. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J. Virol. 2006, 80:3112-3115.
43. Yamashita T., Kamada K., Hatcho K., Adachi A., Nomaguchi M. Identification of amino acid residues in HIV-1 Vif critical for binding and exclusion of APOBEC3G/F. Microbes Infect./Inst. Pasteur 2008, 10:1142-1149.
44. Yamashita T., Nomaguchi M., Miyake A., Uchiyama T., Adachi A. Status of APOBEC3G/F in cells and progeny virions modulated by Vif determines HIV-1 infectivity. Microbes Infect./Inst. Pasteur 2010, 12:166-171.
45. Yang Y., Guo F., Cen S., Kleiman L. Inhibition of initiation of reverse transcription in HIV-1 by human APOBEC3F. Virology 2007, 365:92-100.
46. Yu Q., Konig R., Pillai S., Chiles K., Kearney M., Palmer S., Richman D., Coffin J.M., Landau N.R. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat. Struct. Mol. Biol. 2004, 11:435-442.
47. Zhang H., Yang B., Pomerantz R.J., Zhang C., Arunachalam S.C., Gao L. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 2003, 424:94-98.
48. Zhang W., Chen G., Niewiadomska A.M., Xu R., Yu X.F. Distinct determinants in HIV-1 Vif and human APOBEC3 proteins are required for the suppression of diverse host anti-viral proteins. PLoS One. e3963 2008, 3.